Open Payments

Monument Health Rapid City Hospital

Type
Teaching hospital
Where
Rapid City, SD
Medicare CCN
430077
Received
$1,126,367 in 247 records, 2022 ($80,077 general, $1,046,289 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2022General payment51$80,077
2022Research payment196$1,046,289

By company

CompanyRecordsAmountYears
Novartis Pharmaceuticals Corporation7$600,9542022
American Regent8$97,7292022
AstraZeneca Pharmaceuticals LP7$73,0472022
Esperion Therapeutics, Inc.112$67,2882022
Amgen Inc.4$55,4822022
Eli Lilly and Company6$43,8062022
AstraZeneca UK Limited3$39,4582022
Stryker Corporation9$28,6232022
Boston Scientific Corporation18$23,5072022
KCI USA, Inc.1$21,3752022
Novo Nordisk AS9$12,4842022
Linde Gas & Equipment Inc.23$8,8012022
Boehringer Ingelheim Pharmaceuticals, Inc.2$7,7882022
JAZZ PHARMACEUTICALS INC.6$6,5202022
Medtronic, Inc.1$6,4112022
Zimmer Biomet Holdings, Inc.1$5,0002022
Genentech, Inc.1$5,0002022
CSL Behring14$4,8112022
DiaSorin Inc.1$4,0302022
AngioDynamics, Inc.1$2,7062022
Gilead Sciences, Inc.1$2,5002022
E.R. Squibb & Sons, L.L.C.2$2,0002022
Merck Sharp & Dohme LLC1$1,0002022
PFIZER INC.1$1,0002022
Alnylam Pharmaceuticals Inc.1$1,0002022
ABBVIE INC.1$1,0002022
Lilly USA, LLC1$7502022
Abbott Laboratories1$7502022
Penumbra, Inc.1$7502022
Contego Medical, Inc1$5002022
Hikma Pharmaceuticals USA1$2092022
Merge Healthcare Incorporated1$802022

By nature of payment

NatureRecordsAmount
Research payment196$1,046,289
Long term medical supply or device loan10$31,329
Debt forgiveness1$21,375
Space rental or facility fees (teaching hospital only)34$20,301
Compensation for services other than consulting, including serving as faculty or as a speaker at a v3$5,780
Grant1$1,000
Food and Beverage2$289

Records

DateCompanyAmountNatureFormProductStudyYear
2022-12-31Stryker Corporation$10,942Long term medical supply or device loanIn-kind items and servicesINTOUCH Device, PATIENT CARE - PC2022
2022-12-31AstraZeneca Pharmaceuticals LP$6,195Research paymentIn-kind items and servicesA Phase IIB Randomized Double blinded Placebo controlled Parallel group Study to Evaluate the Efficacy and Safety of MED2022
2022-12-31AstraZeneca UK Limited$5,062Research paymentIn-kind items and servicesA Phase IIB Randomized Double blinded Placebo controlled Parallel group Study to Evaluate the Efficacy and Safety of MED2022
2022-12-31Stryker Corporation$4,420Long term medical supply or device loanIn-kind items and servicesISOLIBRIUM Device, PATIENT CARE - PC2022
2022-12-31Stryker Corporation$2,813Long term medical supply or device loanIn-kind items and servicesPROCUITY Device, PATIENT HANDLING - PH2022
2022-12-31AngioDynamics, Inc.$2,706Long term medical supply or device loanIn-kind items and servicesVenaCure 1470 Pro Device, ET2022
2022-12-31Stryker Corporation$2,640Long term medical supply or device loanIn-kind items and servicesPROCUITY Device, PATIENT HANDLING - PH2022
2022-12-31Stryker Corporation$2,329Long term medical supply or device loanIn-kind items and servicesPROCUITY Device, PATIENT HANDLING - PH2022
2022-12-31Stryker Corporation$1,981Long term medical supply or device loanIn-kind items and servicesISOLIBRIUM Device, PATIENT CARE - PC2022
2022-12-31Stryker Corporation$1,522Long term medical supply or device loanIn-kind items and servicesISOLIBRIUM Device, PATIENT CARE - PC2022
2022-12-31Stryker Corporation$1,245Long term medical supply or device loanIn-kind items and servicesISOTOUR Device, PATIENT CARE - PC2022
2022-12-31Stryker Corporation$727Long term medical supply or device loanIn-kind items and servicesISOTOUR Device, PATIENT CARE - PC2022
2022-12-31Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-12-29Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-12-08Eli Lilly and Company$1,199Research paymentIn-kind items and servicesA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PL2022
2022-12-05American Regent$750Research paymentCash or cash equivalentINJECTAFER Drug, Iron Deficiency AnemiaHeart_FID2022
2022-11-30Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-11-28Zimmer Biomet Holdings, Inc.$5,000Research paymentCash or cash equivalentPersona Device, KneesPersona Ti-Nidium Personalized Total Knee System2022
2022-11-23Novo Nordisk AS$2,328Research paymentCash or cash equivalentRybelsus Drug, DiabetesNN9924-44372022
2022-11-21Boston Scientific Corporation$1,124Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTAPPRAISE ATP2022
2022-11-17CSL Behring$618Research paymentIn-kind items and servicesA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2022
2022-11-17CSL Behring$45Research paymentIn-kind items and servicesA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2022
2022-11-17CSL Behring$22Research paymentIn-kind items and servicesA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2022
2022-11-17CSL Behring$4Research paymentIn-kind items and servicesA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2022
2022-11-16Medtronic, Inc.$6,411Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2022
2022-11-14Novo Nordisk AS$7,114Research paymentCash or cash equivalentWegovy Drug, ObesityNN9536-44512022
2022-11-14Novo Nordisk AS$250Research paymentCash or cash equivalentWegovy Drug, ObesityNN9536-44512022
2022-11-14Novo Nordisk AS$150Research paymentCash or cash equivalentWegovy Drug, ObesityNN9536-44512022
2022-11-09American Regent$7,076Research paymentCash or cash equivalentINJECTAFER Drug, Iron Deficiency AnemiaHeart_FID2022
2022-11-07Boehringer Ingelheim Pharmaceuticals, Inc.$750Space rental or facility fees (teaching hospital only)Cash or cash equivalent2022
2022-11-07Boston Scientific Corporation$202Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTELEGANCE2022
2022-11-07Boston Scientific Corporation$65Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTELEGANCE2022
2022-11-04Esperion Therapeutics, Inc.$825Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-11-03Amgen Inc.$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentRepatha Biological, Cardiology2022
2022-11-03Lilly USA, LLC$750Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2022
2022-11-02JAZZ PHARMACEUTICALS INC.$208Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYEMERGE 402: PHASE IV OBSERVATIONAL STUDY TO COLLECT SAFETY AND OUTCOME DATA IN REAL-WORLD SETTING IN ADULT PATIENTS WITH2022
2022-11-02JAZZ PHARMACEUTICALS INC.$93Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYEMERGE 402: PHASE IV OBSERVATIONAL STUDY TO COLLECT SAFETY AND OUTCOME DATA IN REAL-WORLD SETTING IN ADULT PATIENTS WITH2022
2022-10-20Merck Sharp & Dohme LLC$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentVERQUVO Drug, CARDIOVASCULAR2022
2022-10-17American Regent$12,128Research paymentCash or cash equivalentINJECTAFER Drug, Iron Deficiency AnemiaHeart_FID2022
2022-10-07Esperion Therapeutics, Inc.$120Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-10-04E.R. Squibb & Sons, L.L.C.$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentELIQUIS Drug, Cardiovascular2022
2022-10-04E.R. Squibb & Sons, L.L.C.$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentCAMZYOS Drug, Cardiovascular2022
2022-10-03Esperion Therapeutics, Inc.$1,200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-10-01KCI USA, Inc.$21,375Debt forgivenessCash or cash equivalent2022
2022-09-30PFIZER INC.$1,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVYNDAQEL Drug, CARDIOVASCULAR2022
2022-09-20Boston Scientific Corporation$1,523Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTAPPRAISE ATP2022
2022-09-19Alnylam Pharmaceuticals Inc.$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentAMVUTTRA Drug, Genetic Disease2022
2022-09-16DiaSorin Inc.$4,030Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2022
2022-09-12Esperion Therapeutics, Inc.$120Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-09-07AstraZeneca Pharmaceuticals LP$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentBRILINTA Drug, Cardiovascular and Metabolism2022
2022-09-06Boston Scientific Corporation$455Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTELEGANCE2022
2022-09-02Genentech, Inc.$5,000Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyTIRAGOLUMAB TECENTRIQ VS DURVALUMAB IN UNRESECTABLE STAGE III NSCLC2022
2022-08-26CSL Behring$30Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2022
2022-08-24Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-08-20Linde Gas & Equipment Inc.$733Space rental or facility fees (teaching hospital only)In-kind items and servicesMM NO800NI-AQ Device, Respiratory2022
2022-08-20Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-08-18Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-10Hikma Pharmaceuticals USA$209Food and BeverageIn-kind items and services2022
2022-08-09Boston Scientific Corporation$1,000GrantCash or cash equivalentGENERAL - THERAPIES Device, THERAPIES2022
2022-08-04Novartis Pharmaceuticals Corporation$27,520Research paymentCash or cash equivalentLEQVIO Drug, CARDIOVASCULARAN OPEN-LABEL EXTENSION TRIAL OF THE PHASE III LIPID-LOWERING TRIALS TO ASSESS THE EFFECT OF LONG TERM DOSING OF INCLISI2022
2022-08-03American Regent$28,121Research paymentCash or cash equivalentINJECTAFER Drug, Iron Deficiency AnemiaHeart_FID2022
2022-08-02AstraZeneca Pharmaceuticals LP$1,000Research paymentCash or cash equivalentFARXIGA Drug, Cardiovascular and MetabolismDapagliflozin in Acute Decompensated Heart Failure2022
2022-08-02AstraZeneca Pharmaceuticals LP$750Space rental or facility fees (teaching hospital only)Cash or cash equivalentFARXIGA Drug, Cardiovascular and Metabolism2022
2022-08-01AstraZeneca UK Limited$14,663Research paymentCash or cash equivalentFARXIGA Drug, Cardiovascular and MetabolismA Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Multi Centre Study to Evaluate the Efficacy, Safety and Tolera2022
2022-08-01Boston Scientific Corporation$594Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTELEGANCE2022
2022-07-21Novartis Pharmaceuticals Corporation$44,272Research paymentCash or cash equivalentLEQVIO Drug, CARDIOVASCULARA RANDOMIZED, CONTROLLED, MULTICENTER, OPEN-LABEL TRIAL COMPARING A POST-DISCHARGE CARE PATHWAY INVOLVING AGGRESSIVE LDL2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-19Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-07-18Boston Scientific Corporation$1,565Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTAPPRAISE ATP2022
2022-07-16Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-07-05Boston Scientific Corporation$594Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTELEGANCE2022
2022-07-01Esperion Therapeutics, Inc.$3,000Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-01Contego Medical, Inc$500Research paymentCash or cash equivalentNeuroguard IEP Device, CardiovascularPerformance II2022
2022-07-01Esperion Therapeutics, Inc.$480Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-29CSL Behring$164Research paymentIn-kind items and servicesA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2022
2022-06-29CSL Behring$2Research paymentIn-kind items and servicesA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2022
2022-06-21Boston Scientific Corporation$7,669Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTLUX DX PERFORM2022
2022-06-20Gilead Sciences, Inc.$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$1,221Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$150Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$150Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$150Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$150Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-17Esperion Therapeutics, Inc.$150Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-14Boehringer Ingelheim Pharmaceuticals, Inc.$7,038Research paymentCash or cash equivalentPhase II dose finding PoCC in DKD2022
2022-06-07Boston Scientific Corporation$4,800Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTELEGANCE2022
2022-05-26Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-05-25Novo Nordisk AS$159Research paymentCash or cash equivalentRybelsus Drug, DiabetesNN9924-44372022
2022-05-24Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-05-23Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-05-23Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-05-23Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-05-21Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-05-20CSL Behring$837Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2022
2022-05-16Boston Scientific Corporation$1,000Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTAPPRAISE ATP2022
2022-05-16Boston Scientific Corporation$501Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTLUX DX PERFORM2022
2022-05-11American Regent$1,209Research paymentCash or cash equivalentINJECTAFER Drug, Iron Deficiency AnemiaHeart_FID2022
2022-05-10Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-05-02Merge Healthcare Incorporated$80Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-04-29CSL Behring$1,000Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2022
2022-04-29CSL Behring$1,000Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2022
2022-04-29Novo Nordisk AS$474Research paymentCash or cash equivalentWegovy Drug, ObesityNN9536-44512022
2022-04-21Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-04-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-04-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-04-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-04-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-04-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-04-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-04-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-04-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-04-21Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-04-20American Regent$13,908Research paymentCash or cash equivalentINJECTAFER Drug, Iron Deficiency AnemiaHeart_FID2022
2022-04-19Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-04-18Boston Scientific Corporation$250Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTLUX DX PERFORM2022
2022-04-13Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-03-31JAZZ PHARMACEUTICALS INC.$1,788Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYEMERGE 402: PHASE IV OBSERVATIONAL STUDY TO COLLECT SAFETY AND OUTCOME DATA IN REAL-WORLD SETTING IN ADULT PATIENTS WITH2022
2022-03-29JAZZ PHARMACEUTICALS INC.$150Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYEMERGE 402: PHASE IV OBSERVATIONAL STUDY TO COLLECT SAFETY AND OUTCOME DATA IN REAL-WORLD SETTING IN ADULT PATIENTS WITH2022
2022-03-26Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-03-24Penumbra, Inc.$750Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionCHEETAH2022
2022-03-22Amgen Inc.$1,701Research paymentCash or cash equivalentRepatha Biological, Cardiology20130295-FOURIER OLE (Ph 4)2022
2022-03-22Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-03-21Eli Lilly and Company$7,410Research paymentCash or cash equivalentA RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS2022
2022-03-21Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-03-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-03-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-03-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-03-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-03-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-03-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-03-21Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-03-18CSL Behring$270Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2022
2022-03-16Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-03-14AstraZeneca UK Limited$19,732Research paymentCash or cash equivalentA Phase IIB Randomized Double blinded Placebo controlled Parallel group Study to Evaluate the Efficacy and Safety of MED2022
2022-03-14Abbott Laboratories$750Space rental or facility fees (teaching hospital only)Cash or cash equivalentFREESTYLE LIBRE 2 Device, Diabetes Care2022
2022-03-11Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-03-10JAZZ PHARMACEUTICALS INC.$4,000Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYEMERGE 402: PHASE IV OBSERVATIONAL STUDY TO COLLECT SAFETY AND OUTCOME DATA IN REAL-WORLD SETTING IN ADULT PATIENTS WITH2022
2022-03-09Esperion Therapeutics, Inc.$240Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-03-07American Regent$1,819Research paymentCash or cash equivalentINJECTAFER Drug, Iron Deficiency AnemiaHeart_FID2022
2022-03-04JAZZ PHARMACEUTICALS INC.$280Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYEMERGE 402: PHASE IV OBSERVATIONAL STUDY TO COLLECT SAFETY AND OUTCOME DATA IN REAL-WORLD SETTING IN ADULT PATIENTS WITH2022
2022-03-03AstraZeneca Pharmaceuticals LP$750Space rental or facility fees (teaching hospital only)Cash or cash equivalentFARXIGA Drug, Cardiovascular and Metabolism2022
2022-03-02Novartis Pharmaceuticals Corporation$76,883Research paymentCash or cash equivalentENTRESTO Drug, CARDIOVASCULARPROSPECTIVE COMPARISON OF ARNI WITH ARB GIVEN FOLLOWING STABILIZATION IN DECOMPENSATED HFPEF (PARAGLIDE-HFPEF)2022
2022-03-01Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-03-01Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-03-01Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-03-01Esperion Therapeutics, Inc.$354Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022

The latest 200 records of 247.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Pennington CountyRapid City city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Rapid City, SD, county Pennington County, SD, state South Dakota; placed by its city name.

MeasurePlace (city or town)
Rapid City, SD
County
Pennington County, SD
State
South Dakota
Population B0100377,946113,512907,428
Population, 2020 census P174,703109,222886,667
Median age B0100239.140.138.0
Under 18 B0100122.0%22.0%24.2%
65 and over B0100120.7%20.1%18.0%
Households B1100132,36846,370365,544
Foreign born B050022.6%2.5%4.0%
Median household income B19013$70,870$74,517$75,081
Median family income B19113$91,802$92,479$96,562
Per capita income B19301$42,204$42,302$40,550
Poverty rate B1700112.5%11.2%11.9%
Unemployment rate B230252.6%3.2%2.9%
Civilian labor force B2302539,45257,369475,223
Mean commute (minutes) B0801317.519.417.8
Bachelor's degree or higher B1500337.0%34.6%31.9%
Housing units B2500135,57751,681408,584
Owner-occupied B2500362.9%69.3%68.6%
Renters B2500337.1%30.7%31.4%
Median home value B25077$299,400$302,200$257,400
Median gross rent B25064$1,109$1,120$946
White, not Hispanic B0300276.3%77.8%79.8%
Black B030021.2%1.1%2.1%
Hispanic or Latino B030026.1%5.7%4.8%
Asian B030021.3%1.2%1.4%
American Indian and Alaska Native B030027.1%6.0%7.1%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Rapid City, SD.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.